neophyr 450 ppm mol/mol medicinski plin, stisnjeni
sol s.p.a. - dušikov(ii) oksid - medicinski plin, stisnjeni - dušikov(ii) oksid 450 ppm / 1 jeklenka - dušikov(ii) oksid
neophyr 1000 ppm mol/mol medicinski plin, stisnjeni
sol s.p.a. - dušikov(ii) oksid - medicinski plin, stisnjeni - dušikov(ii) oksid 1000 ppm / 1 jeklenka - dušikov(ii) oksid
hemlibra
roche registration limited - emicizumab - hemofilija a - antihemoragije - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra se lahko uporablja v vseh starostnih skupinah.
luxturna
novartis europharm limited - voretigene neparvovec - leber congenital amaurosis; retinitis pigmentosa - other ophthalmologicals - luxturna je indiciran za zdravljenje odraslih in pediatričnih bolnikih z izgubo vida zaradi dedne očesne mrežnice distrofija, ki jih povzročajo potrdili biallelic rpe65 mutacije in ki imajo dovolj preživetja celic mrežnice.
pregabalin stada arzneimittel 150 mg trde kapsule
stada arzneimittel ag - pregabalin - kapsula, trda - pregabalin 150 mg / 1 kapsula - pregabalin
pregabalin stada arzneimittel 25 mg trde kapsule
stada arzneimittel ag - pregabalin - kapsula, trda - pregabalin 25 mg / 1 kapsula - pregabalin
pregabalin stada arzneimittel 75 mg trde kapsule
stada arzneimittel ag - pregabalin - kapsula, trda - pregabalin 75 mg / 1 kapsula - pregabalin
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplazme dojke - antineoplastična sredstva - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastična sredstva - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
lusmose 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula - sunitinib